Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data Generated From FFPE Solid Tumor

  Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome
  Copy Number Data Generated From FFPE Solid Tumor Samples for Accelerating
  Cancer Translational Research

Business Wire

SANTA CLARA, Calif. -- April 10, 2013

Affymetrix, Inc. (NASDAQ: AFFX) and BioDiscovery announce the availability of
the Nexus for OncoScan^® Software for analysis of whole genome copy number
data generated from formalin-fixed, paraffin-embedded (FFPE) solid tumor
samples using the OncoScan^® FFPE Express 2.0 Service. Through a joint
arrangement, this software, based on BioDiscovery’s flagship Nexus Copy
Number™, is available to customers who are analyzing data generated using this
service.

Obtaining high-quality copy number data using limited amounts of DNA from
degraded FFPE samples is extremely challenging for cancer researchers.
Utilizing Affymetrix’ unique Molecular Inversion Probe (MIP) technology, the
OncoScan FFPE assay is capable of analyzing highly degraded DNA in FFPE tumor
samples, even from less than 100 ng of starting DNA material, and is currently
available as a service through Affymetrix Research Service Laboratory (ARSL)
based in Santa Clara, California.

OncoScan FFPE Express 2.0 Service has been successfully used by more than 30
leading cancer research institutes, including M. D. Anderson Cancer Center,
University of California San Francisco, and the Huntsman Cancer Institute at
the University of Utah.

“Cancer translational researchers have been able to quickly and easily analyze
hundreds of degraded FFPE samples to correlate copy number aberrations with
outcomes data,” said Andy Last, Executive Vice President of the Genetic
Analysis and Clinical Applications Business Unit at Affymetrix. “Nexus for
OncoScan Software is especially optimized for solid tumor copy number analysis
and can generate whole genome copy number calls from raw data in minutes. We
are very excited to continue to partner with BioDiscovery to bring this
powerful and easy-to-use software to the cancer research community.”

"The OncoScan FFPE assay is an amazing technology for cancer researchers
allowing them to unlock DNA information from masses of archived FFPE samples
to obtain high quality data," said Soheil Shams, President of BioDiscovery.
“Combining the powerful OncoScan FFPE technology with the proven power of
Nexus Copy Number gives scientists a unique solution that is sure to
accelerate cancer research, impact diagnosis, and ultimately lead to better
patient care and treatment. We are very pleased to partner with Affymetrix in
offering this powerful solution.”

A next generation OncoScan FFPE product will be available in late 2013
enabling researchers to perform the assay and analysis in their own lab.
Delivering results in about 48 hours, this new product will provide whole
genome copy number coverage with high resolution in known cancer genes, loss
of heterozygozity (LOH) as well as clinically relevant somatic mutation data -
all from a single assay. An updated version of Nexus for OncoScan Software
will be released in conjunction with the launch.

PLEASE NOTE: Affymetrix^®, the Affymetrix logo, and OncoScan^® trademarks are
the property of Affymetrix, Inc. All other trademarks are the property of
their respective owners.

Products mentioned in this release are for research use only. Not for
diagnostic procedures.

Forward-looking statements

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2012, and other SEC reports for subsequent quarterly periods.

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of
biological systems at the cell, protein, and gene level, facilitating the
rapid translation of bench-top research into clinical and routine use for
human health and wellness.

We strive to provide leadership and support, partnering with our customers in
pharmaceutical, diagnostic, and biotechnology companies, as well as leading
academic, government, and non-profit research institutes in their quest for
answers toward using biology for a better world.

More than 2,300 microarray systems have been shipped around the world and more
than 48,000 peer-reviewed papers have been published citing our technologies.
Affymetrix is headquartered in Santa Clara, California, and has manufacturing
facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company
has about 1,100 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.

About BioDiscovery, Inc.

BioDiscovery (www.biodiscovery.com) is a leader in the development of
breakthrough software and services for advanced copy number variation and
expression analysis, enabling customers in drug discovery, research, and
diagnostics by efficiently managing, integrating, and analyzing data generated
using high-throughput microarray and next-generation sequencing technologies.

BioDiscovery Nexus Copy Number software offers simple yet powerful tools for
copy number and sequence variation analysis and visualization from CGH arrays,
SNP arrays, as well as next-generation sequencing, for analysis of complex
data such as solid tumor samples. The elegant user-interface and powerful
statistical tools designed specifically for the end-user allow detection of
chromosomal aberrations and identification of affected pathways with just a
few mouse clicks.

Contact:

Affymetrix, Inc.
Media:
Mindy Lee-Olsen, 408-731-5523
Vice President, Marketing Services
mindy_lee-olsen@affymetrix.com
or
Investors:
Doug Farrell, 408-731-5285
Vice President, Investor Relations
doug_farrell@affymetrix.com
or
BioDiscovery, Inc.
Media:
Louis Culot, 310-414-8100
Vice President, Business Development and Marketing
lculot@biodiscovery.com
 
Press spacebar to pause and continue. Press esc to stop.